Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
7
×
europe top stories
fda
7
×
indiana blog main
indiana top stories
life sciences
national
7
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
startups
alzheimer's disease
cancer immunotherapy
gilead sciences
amag pharmaceuticals
cancer
clinical trials
deals
merck
philadelphia blog main
What
bio
7
×
roundup
cancer
amid
bombast
caught
coronavirus
covid
days
debate
develop
discussion
efforts
ipo
medicines
meso’s
miss
pandemic
pfizer’s
presidential
promise
response
tuesday’s
vaccine
viewers
abbvie’s
acquisitions
activity
ahead
alliance
announced
approvals
biofourmis
biogen
black
bristol
bucks
buy
calls
celebrate
Language
unset
7
×
Current search:
fda
×
biotech
×
" europe blog main "
×
unset
×
national
×
bio
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More